Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: A randomized, controlled trial

Alexander Kainz, Julia Wilflingseder, Christa Mitterbauer, Maria Haller, Christopher Burghuber, Paul Perco, Robert M. Langer, Georg Heinze, Rainer Oberbauer

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: Posttransplantation acute renal failure (ARF) occurs in roughly 25% of recipients of organs from deceased donors. Inflammation in the donor organ is associated with risk for ARF. Objective: To determine whether administering corticosteroids to deceased organ donors reduces the incidence and duration of ARF in organ recipients more than placebo. Design: Parallel, blocked randomized trial, performed between February 2006 and November 2008, with computer-generated randomization and centralized allocation. Investigators were masked to group assignment. (Controlled-trials.com registration number: ISRCTN78828338) Setting: 3 renal transplantation centers in Austria and Hungary. Patients: 306 deceased heart-beating donors and 455 renal transplant recipients. Interventions: Organ donors were administered an intravenous infusion of either 1000 mg of methylprednisolone (136 donors) or placebo (0.9% saline) (133 donors) at least 3 hours before organ harvesting. Measurements: Incidence of ARF, defined as more than 1 dialysis session in the first week after transplantation, was the primary end point. Secondary and other end points included duration of ARF and trajectories of serum creatinine level. The suppression of immune response and inflammation by the intervention was assessed in the donor organ on a genome-wide basis. Results: 52 of 238 recipients (22%) of kidneys from steroid-treated donors and 54 of 217 recipients (25%) of kidneys from placebo-treated donors had ARF (difference, 3 percentage points [95% CI, -11 to 5 percentage points]). One graft was lost on day 1 in each group, and 1 recipient in the placebo group died of cardiac arrest on day 2. The median duration of ARF was 5 days (interquartile range, 2 days) in the steroid group and 4 days (interquartile range, 2 days) in the placebo group (P = 0.31). The groups had similar trajectories of serum creatinine level in the first week (P = 0.72). Genomic analysis showed suppressed inflammation and immune response in kidney biopsies from deceased donors who received corticosteroids. Limitation: Donors and recipients were mainly white, and all were from 3 transplantation centers in central Europe, which may limit generalizability. Conclusion: Systemic suppression of inflammation in deceased donors by corticosteroids did not reduce the incidence or duration of posttransplantation ARF in allograft recipients. Primary Funding Source: Austrian Science Fund and Austrian Academy of Science.

Original languageEnglish
Pages (from-to)222-230
Number of pages9
JournalAnnals of Internal Medicine
Volume153
Issue number4
Publication statusPublished - Aug 17 2010

Fingerprint

Renal Insufficiency
Allografts
Randomized Controlled Trials
Steroids
Tissue Donors
Acute Kidney Injury
Placebos
Inflammation
Kidney
Adrenal Cortex Hormones
Austria-Hungary
Creatinine
Incidence
Transplantation
Tissue and Organ Harvesting
Methylprednisolone
Random Allocation
Heart Arrest
Serum
Intravenous Infusions

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Kainz, A., Wilflingseder, J., Mitterbauer, C., Haller, M., Burghuber, C., Perco, P., ... Oberbauer, R. (2010). Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: A randomized, controlled trial. Annals of Internal Medicine, 153(4), 222-230.

Steroid pretreatment of organ donors to prevent postischemic renal allograft failure : A randomized, controlled trial. / Kainz, Alexander; Wilflingseder, Julia; Mitterbauer, Christa; Haller, Maria; Burghuber, Christopher; Perco, Paul; Langer, Robert M.; Heinze, Georg; Oberbauer, Rainer.

In: Annals of Internal Medicine, Vol. 153, No. 4, 17.08.2010, p. 222-230.

Research output: Contribution to journalArticle

Kainz, A, Wilflingseder, J, Mitterbauer, C, Haller, M, Burghuber, C, Perco, P, Langer, RM, Heinze, G & Oberbauer, R 2010, 'Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: A randomized, controlled trial', Annals of Internal Medicine, vol. 153, no. 4, pp. 222-230.
Kainz A, Wilflingseder J, Mitterbauer C, Haller M, Burghuber C, Perco P et al. Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: A randomized, controlled trial. Annals of Internal Medicine. 2010 Aug 17;153(4):222-230.
Kainz, Alexander ; Wilflingseder, Julia ; Mitterbauer, Christa ; Haller, Maria ; Burghuber, Christopher ; Perco, Paul ; Langer, Robert M. ; Heinze, Georg ; Oberbauer, Rainer. / Steroid pretreatment of organ donors to prevent postischemic renal allograft failure : A randomized, controlled trial. In: Annals of Internal Medicine. 2010 ; Vol. 153, No. 4. pp. 222-230.
@article{dc8bea86271442ee94bdbf8dc9648c63,
title = "Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: A randomized, controlled trial",
abstract = "Background: Posttransplantation acute renal failure (ARF) occurs in roughly 25{\%} of recipients of organs from deceased donors. Inflammation in the donor organ is associated with risk for ARF. Objective: To determine whether administering corticosteroids to deceased organ donors reduces the incidence and duration of ARF in organ recipients more than placebo. Design: Parallel, blocked randomized trial, performed between February 2006 and November 2008, with computer-generated randomization and centralized allocation. Investigators were masked to group assignment. (Controlled-trials.com registration number: ISRCTN78828338) Setting: 3 renal transplantation centers in Austria and Hungary. Patients: 306 deceased heart-beating donors and 455 renal transplant recipients. Interventions: Organ donors were administered an intravenous infusion of either 1000 mg of methylprednisolone (136 donors) or placebo (0.9{\%} saline) (133 donors) at least 3 hours before organ harvesting. Measurements: Incidence of ARF, defined as more than 1 dialysis session in the first week after transplantation, was the primary end point. Secondary and other end points included duration of ARF and trajectories of serum creatinine level. The suppression of immune response and inflammation by the intervention was assessed in the donor organ on a genome-wide basis. Results: 52 of 238 recipients (22{\%}) of kidneys from steroid-treated donors and 54 of 217 recipients (25{\%}) of kidneys from placebo-treated donors had ARF (difference, 3 percentage points [95{\%} CI, -11 to 5 percentage points]). One graft was lost on day 1 in each group, and 1 recipient in the placebo group died of cardiac arrest on day 2. The median duration of ARF was 5 days (interquartile range, 2 days) in the steroid group and 4 days (interquartile range, 2 days) in the placebo group (P = 0.31). The groups had similar trajectories of serum creatinine level in the first week (P = 0.72). Genomic analysis showed suppressed inflammation and immune response in kidney biopsies from deceased donors who received corticosteroids. Limitation: Donors and recipients were mainly white, and all were from 3 transplantation centers in central Europe, which may limit generalizability. Conclusion: Systemic suppression of inflammation in deceased donors by corticosteroids did not reduce the incidence or duration of posttransplantation ARF in allograft recipients. Primary Funding Source: Austrian Science Fund and Austrian Academy of Science.",
author = "Alexander Kainz and Julia Wilflingseder and Christa Mitterbauer and Maria Haller and Christopher Burghuber and Paul Perco and Langer, {Robert M.} and Georg Heinze and Rainer Oberbauer",
year = "2010",
month = "8",
day = "17",
language = "English",
volume = "153",
pages = "222--230",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4",

}

TY - JOUR

T1 - Steroid pretreatment of organ donors to prevent postischemic renal allograft failure

T2 - A randomized, controlled trial

AU - Kainz, Alexander

AU - Wilflingseder, Julia

AU - Mitterbauer, Christa

AU - Haller, Maria

AU - Burghuber, Christopher

AU - Perco, Paul

AU - Langer, Robert M.

AU - Heinze, Georg

AU - Oberbauer, Rainer

PY - 2010/8/17

Y1 - 2010/8/17

N2 - Background: Posttransplantation acute renal failure (ARF) occurs in roughly 25% of recipients of organs from deceased donors. Inflammation in the donor organ is associated with risk for ARF. Objective: To determine whether administering corticosteroids to deceased organ donors reduces the incidence and duration of ARF in organ recipients more than placebo. Design: Parallel, blocked randomized trial, performed between February 2006 and November 2008, with computer-generated randomization and centralized allocation. Investigators were masked to group assignment. (Controlled-trials.com registration number: ISRCTN78828338) Setting: 3 renal transplantation centers in Austria and Hungary. Patients: 306 deceased heart-beating donors and 455 renal transplant recipients. Interventions: Organ donors were administered an intravenous infusion of either 1000 mg of methylprednisolone (136 donors) or placebo (0.9% saline) (133 donors) at least 3 hours before organ harvesting. Measurements: Incidence of ARF, defined as more than 1 dialysis session in the first week after transplantation, was the primary end point. Secondary and other end points included duration of ARF and trajectories of serum creatinine level. The suppression of immune response and inflammation by the intervention was assessed in the donor organ on a genome-wide basis. Results: 52 of 238 recipients (22%) of kidneys from steroid-treated donors and 54 of 217 recipients (25%) of kidneys from placebo-treated donors had ARF (difference, 3 percentage points [95% CI, -11 to 5 percentage points]). One graft was lost on day 1 in each group, and 1 recipient in the placebo group died of cardiac arrest on day 2. The median duration of ARF was 5 days (interquartile range, 2 days) in the steroid group and 4 days (interquartile range, 2 days) in the placebo group (P = 0.31). The groups had similar trajectories of serum creatinine level in the first week (P = 0.72). Genomic analysis showed suppressed inflammation and immune response in kidney biopsies from deceased donors who received corticosteroids. Limitation: Donors and recipients were mainly white, and all were from 3 transplantation centers in central Europe, which may limit generalizability. Conclusion: Systemic suppression of inflammation in deceased donors by corticosteroids did not reduce the incidence or duration of posttransplantation ARF in allograft recipients. Primary Funding Source: Austrian Science Fund and Austrian Academy of Science.

AB - Background: Posttransplantation acute renal failure (ARF) occurs in roughly 25% of recipients of organs from deceased donors. Inflammation in the donor organ is associated with risk for ARF. Objective: To determine whether administering corticosteroids to deceased organ donors reduces the incidence and duration of ARF in organ recipients more than placebo. Design: Parallel, blocked randomized trial, performed between February 2006 and November 2008, with computer-generated randomization and centralized allocation. Investigators were masked to group assignment. (Controlled-trials.com registration number: ISRCTN78828338) Setting: 3 renal transplantation centers in Austria and Hungary. Patients: 306 deceased heart-beating donors and 455 renal transplant recipients. Interventions: Organ donors were administered an intravenous infusion of either 1000 mg of methylprednisolone (136 donors) or placebo (0.9% saline) (133 donors) at least 3 hours before organ harvesting. Measurements: Incidence of ARF, defined as more than 1 dialysis session in the first week after transplantation, was the primary end point. Secondary and other end points included duration of ARF and trajectories of serum creatinine level. The suppression of immune response and inflammation by the intervention was assessed in the donor organ on a genome-wide basis. Results: 52 of 238 recipients (22%) of kidneys from steroid-treated donors and 54 of 217 recipients (25%) of kidneys from placebo-treated donors had ARF (difference, 3 percentage points [95% CI, -11 to 5 percentage points]). One graft was lost on day 1 in each group, and 1 recipient in the placebo group died of cardiac arrest on day 2. The median duration of ARF was 5 days (interquartile range, 2 days) in the steroid group and 4 days (interquartile range, 2 days) in the placebo group (P = 0.31). The groups had similar trajectories of serum creatinine level in the first week (P = 0.72). Genomic analysis showed suppressed inflammation and immune response in kidney biopsies from deceased donors who received corticosteroids. Limitation: Donors and recipients were mainly white, and all were from 3 transplantation centers in central Europe, which may limit generalizability. Conclusion: Systemic suppression of inflammation in deceased donors by corticosteroids did not reduce the incidence or duration of posttransplantation ARF in allograft recipients. Primary Funding Source: Austrian Science Fund and Austrian Academy of Science.

UR - http://www.scopus.com/inward/record.url?scp=77956401027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956401027&partnerID=8YFLogxK

M3 - Article

C2 - 20713790

AN - SCOPUS:77956401027

VL - 153

SP - 222

EP - 230

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4

ER -